Search

Your search keyword '"Yinggan Zheng"' showing total 5 results
Start Over Author "Yinggan Zheng" Journal journal of the american college of cardiology
5 results on '"Yinggan Zheng"'

1. NT-PROBNP DURING SCREENING IN THE STUDY OF VERICIGUAT IN PARTICIPANTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (VICTORIA) TRIAL: INSIGHTS INTO OUTCOMES AND VERICIGUAT

Author

Cynthia M. Westerhout, Yinggan Zheng, Lars Lund, Javed Butler, Richard W. Troughton, Michele Emdin, Carolyn S.P. Lam, Piotr Ponikowski, Robert Blaustein, Christopher M. O'Connor, Lothar Roessig, Adriaan Voors, Justin A. Ezekowitz, and Paul Wayne Armstrong

Subjects
Cardiology and Cardiovascular Medicine
Published
2023

3. ASSOCIATIONS BETWEEN BETA-BLOCKER THERAPY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIABETES AND ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM THE TECOS STUDY

Author

Paul W. Armstrong, Matthew T. Roe, Cynthia M. Westerhout, Yinggan Zheng, Darren K. McGuire, Jay Shavadia, Eric D. Peterson, Jennifer B. Green, Jan H. Cornel, and Rury R. Holman

Subjects
Secondary prevention, medicine.medical_specialty, Proportional hazards model, Atherosclerotic cardiovascular disease, Beta blocker therapy, business.industry, Type 2 diabetes, medicine.disease, Diabetes mellitus, Internal medicine, medicine, In patient, Cardiology and Cardiovascular Medicine, business, Cardiovascular outcomes
Abstract

The secondary prevention effects of beta-blocker therapy (BBT) in type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) are unclear. Using an inverse probability of treatment-weighted Cox proportional hazards model, we examined the association between baseline BBT and

Published
2019

4. APPLICATION OF TICAGRELOR OR CLOPIDOGREL BASED DUAL ANTIPLATELET THERAPY FOLLOWING A PHARMACOINVASIVE STRATEGY IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE VITAL HEART RESPONSE REGISTRY

Author

R. Leung, Yinggan Zheng, Kevin R. Bainey, Jay Shavadia, Benjamin Tyrrell, Neil Brass, and Robert C. Welsh

Subjects
medicine.medical_specialty, Standard of care, business.industry, medicine.medical_treatment, medicine.disease, Clopidogrel, Internal medicine, Fibrinolysis, medicine, Cardiology, ST segment, cardiovascular diseases, Myocardial infarction, Cardiology and Cardiovascular Medicine, business, Ticagrelor, circulatory and respiratory physiology, medicine.drug
Abstract

Ticagrelor (TIC) based dual antiplatelet therapy (DAPT) is standard of care for acute coronary syndromes (ACS) with the exception of fibrinolysis treated ST-segment elevation myocardial infarction (STEMI) patients where clopidogrel (CLOP) is recommended. Although comparable 30-day safety was shown

Published
2019

5. REAL WORLD RELATIONSHIPS BETWEEN BASELINE Q WAVES, TIME FROM SYMPTOM ONSET AND CLINICAL OUTCOMES IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION PATIENTS: INSIGHT FROM THE VITAL HEART RESPONSE REGISTRY

Author

Robert C. Welsh, Kevin R. Bainey, Ben Tyrrell, Paul W. Armstrong, Yinggan Zheng, and Neil Brass

Subjects
medicine.medical_specialty, business.industry, medicine.disease, Clinical trial, surgical procedures, operative, Internal medicine, Cardiology, Medicine, ST segment, cardiovascular diseases, Symptom onset, Myocardial infarction, Cardiology and Cardiovascular Medicine, business, Baseline (configuration management)
Abstract

Background: Baseline Q waves on the initial 12-lead ECG in clinical trials has been shown to be a simple predictor of clinical outcomes in STEMI patients. Whether this relationship applies in real world STEMI care is unknown. Using a large comprehensive STEMI registry, we evaluated the relationships

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results